Investment accounts
Adult accounts
Child accounts
Choosing Fidelity
Choosing Fidelity
Why invest with us Current offers Fees and charges Open an account Transfer investments
Financial advice & support
Fidelity’s Services
Fidelity’s Services
Financial advice Retirement Wealth Management Investor Centre (London) Bereavement
Guidance and tools
Guidance and tools
Choosing investments Choosing accounts ISA calculator Retirement calculators
Share dealing
Choose your shares
Tools and information
Tools and information
Share prices and markets Chart and compare shares Stock market news Shareholder perks IPOs and placings
Pensions & retirement
Pensions, tax & tools
Saving for retirement
Approaching / In retirement
Approaching / In retirement
Speak to a specialist Creating a retirement plan Taking tax-free cash Pension drawdown Annuities Investing in retirement Investment Pathways
Faron Pharmaceuticals reports year of clinical progress
(Sharecast News) - Clinical-stage biopharmaceutical company Faron Pharmaceuticals reported a year of strong progress on Wednesday, with significant overall response rates seen in both previously hypomethylating agent (HMA)-failed and higher-risk myelodysplastic syndrome (MDS) patient populations in the phase one part of the BEXMAB study. The AIM-traded firm, which is pre-revenue, said most responses were deep and durable, with notable achievements such as complete remission/marrow complete remission (CR/mCR) and partial remission (PR) observed in treated patients.
It said the findings led to the start of the phase two part of the BEXMAB study, guided by the US Food and Drug Administration (FDA), investigating bexmarilimab in combination with standard of care (SoC) in patients with HMA-refractory or relapsed MDS.
Additionally, the FDA granted bexmarilimab orphan drug designation (ODD) for the treatment of acute myeloid leukaemia (AML).
The company also reported that the MATINS study demonstrated promising results in advanced solid tumour patients, with bexmarilimab showing tolerability, activation of intratumoral immunity, and favourable changes in the tumour microenvironment (TME), providing significant clinical benefit.
Throughout 2023, Faron successfully conducted three fundraising rounds, raising €25.7m.
Since the end of the year, in January, Faron dosed the first patients in the phase two part of the BEXMAB Study, marking progress towards evaluating the safety and efficacy of bexmarilimab in combination with SoC in HMA-refractory or relapsed MDS patients.
However, in February, the company disclosed breaches in undertakings agreed in a facilities agreement, leading to several events of default.
Despite that, Faron said it managed to secure €3.2m in subordinated convertible loan arrangements in March, allowing critical payments to third parties under agreed waivers with IPF.
The company said it was now in compliance with all IPF financial covenants, actively engaged in discussions to secure short- and long-term funding.
"I am pleased to report that we have made strong progress in 2023 advancing our BEXMAB study of bexmarilimab, our wholly owned immunotherapy asset," said chief executive officer Dr Markku Jalkanen.
"Throughout the course of the year, we have reported highly encouraging data for bexmarilimab, showing a remarkable overall response rate in both higher-risk frontline MDS patients as well as HMA-failed MDS patients."
Dr Jalkanen described the findings as "highly significant", given the combinations of treatments the patients had previously failed on and the very limited options available for future therapy.
"They provide us with a path to market and only bolster our confidence in the potential of this novel immunotherapy to treat patients with aggressive haematological malignancies."
At 1012 GMT, Faron Pharmaceuticals shares were down 3.67% at 130.05p.
Reporting by Josh White for Sharecast.com.
Share this article
Related Sharecast Articles
Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.
Award-winning online share dealing
Search, compare and select from thousands of shares.
Expert insights into investing your money
Our team of experts explore the world of share dealing.
Policies and important information
Accessibility | Conflicts of interest statement | Consumer Duty Target Market | Consumer Duty Value Assessment Statement | Cookie policy | Diversity and Inclusion | Doing Business with Fidelity | Fidelity gender pay report | Investing in Fidelity funds | Legal information | Modern slavery | Mutual respect policy | Privacy statement | Remuneration policy | Security | Statutory and Regulatory disclosures | Whistleblowing policy
Please remember that past performance is not necessarily a guide to future performance, the performance of investments is not guaranteed, and the value of your investments can go down as well as up, so you may get back less than you invest. When investments have particular tax features, these will depend on your personal circumstances and tax rules may change in the future. This website does not contain any personal recommendations for a particular course of action, service or product. You should regularly review your investment objectives and choices and, if you are unsure whether an investment is suitable for you, you should contact an authorised financial adviser. Before opening an account, please read the ‘Doing Business with Fidelity’ document which incorporates our client terms. Prior to investing into a fund, please read the relevant key information document which contains important information about the fund.
This website is issued by Financial Administration Services Limited, which is authorised and regulated by the Financial Conduct Authority (FCA) (FCA Register number 122169) and registered in England and Wales under company number 1629709 whose registered address is Beech Gate, Millfield Lane, Lower Kingswood, Tadworth, Surrey, KT20 6RP.